Pharmaceuticals company Caplin Point Laboratories announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Gross Margin: 60% vs. 56.6% in Q4FY24 — aided by new product launches across existing and new markets. Revenue from Operations: Rs 502.5 crore vs. Rs 453.2 crore in Q4FY24 — up 10.9% YoY. EBITDA: Rs 193.8 crore vs. Rs 162.5 crore in Q4FY24 — up 19.2% YoY. EBITDA Margin: 36.7% vs. 34.5% in Q4FY24 Profit After Tax (PAT): Rs 145.3 crore vs. Rs 121.2 crore in Q4FY24 — up 19.8% YoY. FY25 Financial Highlights: FY25 Total Revenue at Rs 2034 crore; an increase of 15.5% YoY FY 25 PAT at Rs 541 crore; (Growth of 17.3% over FY24) EBITDA Margin: 36.5% vs. 35.1% in FY24 Basic EPS increased by 17.2% to Rs 70.57 in FY25 compared to Rs 60.19 in FY24. Cash Flow from Operations in FY25 is Rs 432.39 crore vs Rs 318 crore in FY24. CSL's Total revenue crosses Rs 366 crore, an increase of 15% over FY24. US Market FY25 EBIDTA crosses Rs 102 crore (Growth of 71% over FY24) Free Cash Reserves at Rs 1,180 crore; Liquid Assets at Rs 2,148 crore Commenting on the performance, C.C. Paarthipan, Chairman said: "We’re delighted to close out another year with excellent Top and Bottom Line Growth, and continue our progress on being a benchmark when it comes to Cashflows. Our front end in the US is taking shape at a good pace and we expect this entity to drive strong growth for the parent company over the next few years. We’re once again focusing on getting back to Asset Light outsourcing using our Second Innings at China, with import of Peptides and Key starting materials for Biosimilars, which we plan to file and launch in our Emerging Markets where we have a significant presence already. With our API entities coming on stream in the very near future, we can truly envision Caplin being a fully integrated global Pharma player in the years to come." Result PDF
Conference Call with Caplin Point Laboratories Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Caplin Point Laboratories announced Q3FY25 results Revenue: Rs 493.0 crore compared to Rs 435.5 crore during Q3FY24, change 13.2%. EBITDA: Rs 193.7 crore compared to Rs 159.5 crore during Q3FY24, change 21.4%. PBT: Rs 177.3 crore compared to Rs 145.4 crore during Q3FY24, change 21.9%. PAT: Rs 140.1 crore compared to Rs 119.8 crore during Q3FY24, change 16.9%. Gross Margin for Q3FY25 is 60.4% vs 56.3% in Q3 FY24. EBITDA Margin for Q3FY25 is at 36.9% vs 35.2% in Q3 FY24. As of 31st December 2024, Inventories are at Rs 333 crore - 52% Stock at the warehouses, close to the customer; In Transit 18%; 30% in India. Receivables is at 118 days. As of 31st December, 2024 Free Cash reserves are at Rs 1,081 crore and Total Liquid Assets at Rs 2,042 crore. C.C. Paarthipan, Chairman, said: We’re happy to report another strong set of numbers for this quarter, underlining our sharp focus on consistency in all areas. The company has shown encouraging progress within a very short period when it comes to the launch of our own label in the US, and with consistent on-time approvals, we’re confident that this entity will deliver robust growth to the organization. We’re making good progress in our key emerging markets of Mexico and Chile, and we can start to see tangible growth from these areas in the next couple of years. The company is well positioned for continued growth in all parameters, with benchmark cashflows for multiple years to come. Result PDF
Pharmaceuticals company Caplin Point Laboratories announced H1FY25 & Q2FY25 results Gross Margin for Q2FY25 is 60.9% vs 60.0% in Q2FY24 and H1FY25 is 60.3% vs 57.4% in H1FY24, aided by new product launches across existing and new markets. EBITDA Margin for Q2FY25 is steady at 36.8% vs 36.7% in Q2FY24 and H1FY25 is 36.3 % vs 35.4% in H1FY24. Basic EPS increased by 16.6% to Rs 33.54 in H1FY25 compared to Rs 28.75 in H1FY24. Cash Flow from Operations in H1FY25 is Rs 186 crore vs Rs 129 crore in H1FY24. Free Cash Flow is Rs 109 crore (after Capex investment of Rs 77 crore) in H1FY25 as compared to Rs 50 crore (after capex investment of Rs 79 crore) in H1FY24. Geographical revenue composition between Latin America & Rest of World and US for H1FY25 is in the range of 82% and 18% respectively. CSL's revenue composition demonstrates a balanced mix of Product Supply and Milestone + Profit Share, with the split for H1FY25 in the range of 75% and 25% respectively. As of Q2FY25, Inventories are at Rs 327 crore - 50% Stock at the warehouses, close to the customer; In Transit 20%; 30% in India. Receivables is at 118 days. As of Q2FY25 Free Cash reserves are at Rs 1,039 crore and Total Liquid Assets at Rs 1,984 crore. C.C. Paarthipan, Chairman, Caplin Point Laboratories, said: Consistency and Stability are key factors in the sustainability of any business. When we add our unique business model of taking the road less travelled and catering to the bottom of the pyramid, you have a potent combination. Our relentless focus towards high degree of compliance, supply chain efficiency and robustness in cashflows has led to another strong quarter, driven both by our Emerging Markets business in LatAm and our growing business in the US. We remain confident of keeping up these fundamentals in the years to come. Result PDF